Usefulness of vernakalant hydrochloride injection for rapid conversion of atrial fibrillation
Research output: Contribution to journal › Journal article › Research › peer-review
The objective of the present study was to assess the safety and effectiveness of vernakalant hydrochloride injection (RSD1235), a novel antiarrhythmic drug, for the conversion of atrial fibrillation (AF) or atrial flutter to sinus rhythm (SR). Patients with either AF or atrial flutter were randomized in a 1:1 ratio to receive vernakalant (n = 138) or placebo (n = 138) and were stratified by an arrhythmia duration of >3 hours to =7 days (short duration) and 8 to =45 days (long duration). The first infusion of placebo or vernakalant (3 mg/kg) was given for 10 minutes followed by a second infusion of placebo or vernakalant (2 mg/kg) 15 minutes later if the arrhythmia had not terminated. A total of 265 patients were randomized and received treatment. The primary end point was conversion of AF to SR for =1 minute within 90 minutes of the start of the drug infusion in the short-duration AF group. Of the 86 patients receiving vernakalant in the short-duration AF group, 44 (51.2%) demonstrated conversion to SR compared to 3 (3.6%) of the 84 in the placebo group (p
Original language | English |
---|---|
Journal | American Journal of Cardiology |
Volume | 106 |
Issue number | 9 |
Pages (from-to) | 1277-83 |
Number of pages | 7 |
ISSN | 0002-9149 |
DOIs | |
Publication status | Published - 1 Nov 2010 |
ID: 34116206